These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17874857)

  • 21. Review of the safety and efficacy of voriconazole.
    Hoffman HL; Rathbun RC
    Expert Opin Investig Drugs; 2002 Mar; 11(3):409-29. PubMed ID: 11866669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
    den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
    J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis.
    Burkhardt O; Thon S; Burhenne J; Welte T; Kielstein JT
    Int J Antimicrob Agents; 2010 Jul; 36(1):93-4. PubMed ID: 20381320
    [No Abstract]   [Full Text] [Related]  

  • 24. Voriconazole: a new triazole antifungal.
    Sabo JA; Abdel-Rahman SM
    Ann Pharmacother; 2000 Sep; 34(9):1032-43. PubMed ID: 10981251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Voriconazole: a new weapon against invasive fungal infections].
    Aoun M
    Rev Med Brux; 2004 Jun; 25(3):166-71. PubMed ID: 15291449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is the "therapeutic range" for voriconazole?
    Lewis RE
    Clin Infect Dis; 2008 Jan; 46(2):212-4. PubMed ID: 18171252
    [No Abstract]   [Full Text] [Related]  

  • 27. Advances in antifungal therapy.
    Pannaraj PS; Walsh TJ; Baker CJ
    Pediatr Infect Dis J; 2005 Oct; 24(10):921-2. PubMed ID: 16220093
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
    Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
    J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA; Kuhn DM
    Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole.
    Antachopoulos C; Papakonstantinou E; Dotis J; Bibashi E; Tamiolaki M; Koliouskas D; Roilides E
    J Pediatr Hematol Oncol; 2005 May; 27(5):283-5. PubMed ID: 15891566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.
    Koh H; Hino M; Ohta K; Iino M; Urase F; Yamaguchi M; Yamanouchi J; Usui N; Yoshida M; Tanimoto M; Ohyashiki K; Urabe A; Tamura K; Kanamaru A; Masaoka T
    J Infect Chemother; 2013 Dec; 19(6):1126-34. PubMed ID: 23813092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection.
    Askari E; Jarque I; Nicolás Franco S; Cáceres Agra JJ
    Rev Esp Quimioter; 2010 Dec; 23(4):210-2. PubMed ID: 21191561
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.
    Walsh TJ; Driscoll T; Milligan PA; Wood ND; Schlamm H; Groll AH; Jafri H; Arrieta AC; Klein NJ; Lutsar I
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4116-23. PubMed ID: 20660687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections.
    Gorski E; Esterly JS; Postelnick M; Trifilio S; Fotis M; Scheetz MH
    Antimicrob Agents Chemother; 2011 Jan; 55(1):184-9. PubMed ID: 20974867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
    Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy.
    Zaragoza R; Pemán J
    Rev Iberoam Micol; 2006 Jun; 23(2):59-63. PubMed ID: 16854178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
    Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
    Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy.
    Hansford JR; Cole C; Blyth CC; Gottardo NG
    J Antimicrob Chemother; 2012 Jul; 67(7):1807-9. PubMed ID: 22454488
    [No Abstract]   [Full Text] [Related]  

  • 39. Voriconazole.
    Med Lett Drugs Ther; 2002 Jul; 44(1135):63-5. PubMed ID: 12138377
    [No Abstract]   [Full Text] [Related]  

  • 40. Voriconazole in newborns.
    Kohli V; Taneja V; Sachdev P; Joshi R
    Indian Pediatr; 2008 Mar; 45(3):236-8. PubMed ID: 18367773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.